New Product Penetration: Understanding & Accelerating New Product Uptake

New Product Penetration: Understanding & Accelerating New Product Uptake summarises the key issues around this important subject. It includes exclusive feedback from in-depth interviews with experienced directors from leading pharmaceutical companies. The report discusses examples of pre and peri-launch tactics companies are using to improve product adoption. It also outlines key questions that you should consider when looking to increase your new product uptake.

Key features of New Product Penetration: Understanding & Accelerating New Product Uptake include:

• Views from global marketing directors of leading pharma companies
• Various tactics to help develop and deliver rapid product uptake
• The need for combined clinical and economic product benefits
• The importance of segmenting the market at a clinical, payer and patient level
• Structural company changes to improve new product penetration
• The role of non-traditional KOL groups in securing market access
• Coordination of cross-functional and geographic launch activities
• Actions that big pharma companies are taking to improve product uptake

With rapidly changing market factors, new opinion leader groups and the importance of a product's clinical-economic benefits, finding effective ways to keep pace with these changes is critical. However, many pharma companies are not aware of this, and remain complacent about taking appropriate action.

In New Product Penetration: Understanding & Accelerating New Product Uptake, FirstWord Dossier reviews the differences between complex pharmaceutical adoption curves versus simple textbook bell curves. It identifies the latest key drivers and barriers to new product penetration. The report also examines strategic tactics that big pharma are now using to improve their uptake curves. This report will help you to:

• Understand the multiple factors that affect new pharma product adoption
• Hear the tactics that industry leaders recommend to improve uptake
• Recognise unresolved issues that still affect rapid product uptake
• Prevent and avert internal and external issues that delay market access
• Review a checklist of key questions to ask when aiming to raise product uptake
• Identify ways to shape the target market uptake of your new products

New Product Penetration: Understanding & Accelerating New Product Uptake answers key questions including:

• Why is the current environment for pharma product uptake so complex?
• Which mechanisms have companies adopted to accelerate new product uptake?
• Why issues to support rapid uptake remain unresolved?
• Which pre and peri-launch steps can effectively raise product uptake?
• How can Phase III trial design affect the uptake of new products?
• Which non-traditional KOL groups are now swaying rapid product uptake?
• How do the clinical vs. economic benefits of products affect growth curves?
• When should you define a product's overall value for your target markets?

”Stalled or uneven product uptake is a classic sign of a lack of strategic segmentation,” Bhupendra Patel, executive director, global marketing, Johnson & Johnson.

“The way we launched in the past, with a good premarketing campaign and a major launch strategy, doesn’t works very well now because payers and governments have put up so many barriers in getting access to the market,” Stephen Lewington, senior director global marketing & medical affairs, Almirall.

“The old, functional way of working created internal barriers to resource allocation. It prevented us from looking at the bigger picture. But the new market-based company structure has been a huge way for us to really accelerate market uptake” Uday Bose, European head of oncology, Eisai.

“Market access strategy can make a lot of difference to speeding up adoption. It's no longer enough, of course, for a product to be approved; somebody needs to pay for it” Ashwin Dandekar, senior vice president, Campbell Associates.

“Key opinion leaders were once synonymous with clinical professionals but this is now a much broader category. The KOLs of the patient advocacy groups have become very influential, and they will be directed by products to help their constituency” Ian Talmage, senior vice president, global marketing, Bayer.